These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32086241)

  • 1. Imaging Responses to Immunotherapy with Novel PET Tracers.
    Niemeijer AL; Hoekstra OS; Smit EF; de Langen AJ
    J Nucl Med; 2020 May; 61(5):641-642. PubMed ID: 32086241
    [No Abstract]   [Full Text] [Related]  

  • 2. Bridging the gaps in
    Campbell MG; Mercier J; Genicot C; Gouverneur V; Hooker JM; Ritter T
    Nat Chem; 2016 Dec; 9(1):1-3. PubMed ID: 27995923
    [No Abstract]   [Full Text] [Related]  

  • 3. Positron emission tomographic imaging in drug discovery.
    Ghosh KK; Padmanabhan P; Yang CT; Ng DCE; Palanivel M; Mishra S; Halldin C; Gulyás B
    Drug Discov Today; 2022 Jan; 27(1):280-291. PubMed ID: 34332093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography in CNS drug discovery and drug monitoring.
    Piel M; Vernaleken I; Rösch F
    J Med Chem; 2014 Nov; 57(22):9232-58. PubMed ID: 25144329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers.
    Shah M; Catafau AM
    J Nucl Med; 2014 Jun; 55(6):871-4. PubMed ID: 24833492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
    Sachpekidis C; Goldschmidt H; Dimitrakopoulou-Strauss A
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31905752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical
    Childs L; Thompson A; Jones H; Hameeduddin A; Ghufoor K; Adams A
    Clin Imaging; 2018; 49():136-143. PubMed ID: 29414508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal tumor models for PET in drug development.
    Toyohara J; Ishiwata K
    Ann Nucl Med; 2011 Dec; 25(10):717-31. PubMed ID: 21879295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving role of PET/CT in breast cancer.
    Groheux D; Giacchetti S; Rubello D; Al-Nahhas A; Moretti JL; Espié M; Hindié E
    Nucl Med Commun; 2010 Apr; 31(4):271-3. PubMed ID: 20375973
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
    Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
    J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorine-containing drugs as PET diagnostics (F-18 labeled tracers).
    Goodman MM; McConathy J
    Curr Top Med Chem; 2013; 13(8):869-70. PubMed ID: 23590165
    [No Abstract]   [Full Text] [Related]  

  • 12. PET imaging of recurrent and metastatic prostate cancer with novel tracers.
    Mertan FV; Lindenberg L; Choyke PL; Turkbey B
    Future Oncol; 2016 Nov; 12(21):2463-2477. PubMed ID: 27527923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging with (11)Carbon labelled PET tracers.
    Fanti S; Nanni C; Lopci E; Castellucci P; Rubello D; Farsad M; Boschi S
    Nucl Med Commun; 2010 Jul; 31(7):613-6. PubMed ID: 20526153
    [No Abstract]   [Full Text] [Related]  

  • 14. Site-Specific Immuno-PET Tracer to Image PD-L1.
    Wissler HL; Ehlerding EB; Lyu Z; Zhao Y; Zhang S; Eshraghi A; Buuh ZY; McGuth JC; Guan Y; Engle JW; Bartlett SJ; Voelz VA; Cai W; Wang RE
    Mol Pharm; 2019 May; 16(5):2028-2036. PubMed ID: 30875232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target.
    Mayer KE; Mall S; Yusufi N; Gosmann D; Steiger K; Russelli L; Bianchi HO; Audehm S; Wagner R; Bräunlein E; Stelzl A; Bassermann F; Weichert W; Weber W; Schwaiger M; D'Alessandria C; Krackhardt AM
    Theranostics; 2018; 8(21):6070-6087. PubMed ID: 30613283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic screening of imaging biomarkers for the Islets of Langerhans, among clinically available positron emission tomography tracers.
    Karlsson F; Antonodimitrakis PC; Eriksson O
    Nucl Med Biol; 2015 Oct; 42(10):762-9. PubMed ID: 26138288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How many PET tracers do we need?
    Schwaiger M; Wester HJ
    J Nucl Med; 2011 Dec; 52 Suppl 2():36S-41S. PubMed ID: 22144553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled glucose derivatives for tumor imaging using SPECT and PET.
    Liu T; Zhang J; Wang X; Yang J; Tang Z; Lu J
    Curr Med Chem; 2014; 21(1):24-34. PubMed ID: 23992343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications.
    Mercier J; Provins L; Valade A
    Drug Discov Today Technol; 2017 Nov; 25():45-52. PubMed ID: 29233267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers.
    Wong KK; Arabi M; Zerizer I; Al-Nahhas A; Rubello D; Gross MD
    Nucl Med Commun; 2011 Sep; 32(9):764-81. PubMed ID: 21799367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.